New hope for kids with tough leukemia: trial tests powerful drug trio
NCT ID NCT06397027
Summary
This study aims to find the safest and most effective dose of a new drug, ziftomenib, when given with two other drugs (venetoclax and azacitidine) to children and young adults whose acute leukemia has come back or hasn't responded to other treatments. It will enroll about 22 participants aged 2 to 21 years old who have specific genetic changes in their cancer. The main goal is to see how well the body handles this combination and to look for early signs that it might help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.